Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab

Trial Profile

Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 14 Feb 2017 Results published in the British Journal of Dermatology
    • 18 May 2016 Status changed from completed to discontinued because of business decision due to slow enrollment.
    • 24 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top